The Oregon Health Authority has released updated public health statements on cannabis, revising guidance first issued in 2015 following the state's legalization of recreational marijuana use.
The 2026 statements are based on an extensive review of scientific literature and reports. They represent a significant update from 2017, reflecting major changes in cannabis policy and the scientific evidence base. Tom Jeanne, M.D., M.P.H., deputy state health officer and epidemiologist at the OHA Public Health Division, said the goal was to "capture as much recent data and evidence as possible...to provide a comprehensive picture of the potential health harms and health benefits of cannabis use."
The statements are intended for clinicians, local public health agencies, legislators, and the public. They describe cannabis terminology, products and potency, consumption methods, and recommendations for individuals considering use.
The guidance identifies moderate or strong evidence linking cannabis use to respiratory diseases, cardiovascular conditions including heart attack and stroke, injuries including motor vehicle crashes, neurological impairment in memory and attention, mental health effects including suicide and psychosis, reproductive and developmental harms to children including low birth weight and reduced cognitive function, and gastrointestinal effects.
The statements also document health benefits supported by moderate or strong evidence: short-term improvement of airflow in the lungs, treatment of chemotherapy-induced nausea and vomiting with pharmaceutical THC, treatment of specific seizure disorders and epilepsy with pharmaceutical CBD and other cannabinoids, improvement of multiple sclerosis spasticity symptoms, and chronic pain relief.
The authority acknowledged limitations in its review, noting that it was conducted by a small team with limited resources and was not as comprehensive as major reviews by organizations such as the Cochrane Collaboration or the National Academies of Sciences, Engineering, and Medicine. Because cannabis products vary by type and potency, the agency cautioned that actual health risks could differ from the findings. The statements should not be considered exhaustive of all cannabis health effects research, which continues to expand.
